• Steven HollenbergEmail author
  • Stephen Heitner
Part of the Current Clinical Practice book series (CCP, volume 1)


Cardiovascular disease (CVD) is the leading cause of death in the United States for both men and women. Although the precise number of people with elevated lipids depends on the definition chosen, it is clear that hyperlipidemia is one of the most important modifiable risk factors for coronary heart disease (CHD) in the United States [1].


Nicotinic Acid Statin Therapy Framingham Risk Score hsCRP Level Bile Acid Sequestrant 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285:2486–96.CrossRefGoogle Scholar
  2. 2.
    Wilson PW et al. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97(18):1837–47.PubMedGoogle Scholar
  3. 3.
    Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol. 1998;81(4A):7B–12.PubMedCrossRefGoogle Scholar
  4. 4.
    Galassi A, Reynolds K, He J. Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. Am J Med. 2006;119(10):812–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Grundy SM et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol. 2004;44(3):720–32.PubMedCrossRefGoogle Scholar
  6. 6.
    Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7–22.CrossRefGoogle Scholar
  7. 7.
    Ridker PM et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195–207.PubMedCrossRefGoogle Scholar
  8. 8.
    Shepherd J et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360(9346):1623–30.PubMedCrossRefGoogle Scholar
  9. 9.
    ALLHAT Investigators. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA. 2002;288(23):2998–3007.CrossRefGoogle Scholar
  10. 10.
    Sever PS et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361(9364):1149–58.PubMedCrossRefGoogle Scholar
  11. 11.
    Cannon CP et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495–504.PubMedCrossRefGoogle Scholar
  12. 12.
    Ridker PM et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352(1):20–8.PubMedCrossRefGoogle Scholar
  13. 13.
    Fonarow GC et al. Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP). Am J Cardiol. 2001;87(7):819–22.PubMedCrossRefGoogle Scholar
  14. 14.
    LaRosa JC et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352(14):1425–35.PubMedCrossRefGoogle Scholar
  15. 15.
    Davidson MH et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol. 2002;40(12):2125–34.PubMedCrossRefGoogle Scholar
  16. 16.
    Kastelein JJ et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008;358(14):1431–43.PubMedCrossRefGoogle Scholar
  17. 17.
    Rossebo AB et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008;359(13):1343–56.PubMedCrossRefGoogle Scholar
  18. 18.
    Peto R et al. Analyses of cancer data from three ezetimibe trials. N Engl J Med. 2008;359(13):1357–66.PubMedCrossRefGoogle Scholar
  19. 19.
    Harris WS et al. Omega-6 fatty acids and risk for cardiovascular disease: a science advisory from the American Heart Association Nutrition Subcommittee of the Council on Nutrition, Physical Activity, and Metabolism; Council on Cardiovascular Nursing; and Council on Epidemiology and Prevention. Circulation. 2009;119(6):902–7.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Cooper University HospitalCamdenUSA
  2. 2.Robert Wood Johnson Medical SchoolUniversity of Medicine and Dentistry of Section of Cardiology Cooper University HospitalCamdenUSA

Personalised recommendations